Editorial Commentary
Is modified FOLFIRINOX a standard regimen for 2nd line chemotherapy for pancreatic cancer after gemcitabine plus nab-paclitaxel failure?—insights from the MPACA-3 trial
Toshihiko Matsumoto, Shogo Yamamura, Hiroki Nagai, Hironaga Satake, Hisateru Yasui